The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluating surgery and first-line imatinib (ima) treatment patterns for patients with gastrointestinal stromal tumors (GIST).
Michael Eaddy
Consultant or Advisory Role - Xcenda
Brian S. Seal
Employment or Leadership Position - Bayer
Mark R. Green
Consultant or Advisory Role - Xcenda
Dana Stafkey-Mailey
Consultant or Advisory Role - Xcenda